Literature DB >> 2562472

The protective effects of intravenous theophylline and enprofylline against histamine- and adenosine 5'-monophosphate-provoked bronchoconstriction: implications for the mechanisms of action of xanthine derivatives in asthma.

H Clarke1, M J Cushley, C G Persson, S T Holgate.   

Abstract

The contribution of adenosine antagonism to the anti-bronchoconstrictor effect of xanthines was examined in 7 atopic asthmatic subjects. On separate occasions the effect of intravenous infusions of theophylline, enprofylline and saline placebo was observed on bronchoconstriction provoked by increasing inhaled concentrations of histamine and adenosine 5'-monophosphate (AMP). Airway calibre was followed as the maximum expiratory flow at 70% below total lung capacity (Vmax30) and FEV1. Both active drugs produced a similar 6-8% increase in FEV1 and 28-41% increase in Vmax30 at steady state plasma concentrations of theophylline 11 mg/ml and enprofylline 3 mg/ml respectively. During the placebo infusion histamine and AMP caused dose-related reductions in both indices of airway calibre, with AMP being approximately 10 times less potent than histamine in molar terms. Theophylline and enprofylline produced similar protection against histamine induced reductions in FEV1 and Vmax30. Whereas enprofylline afforded a similar degree of protection against the airway effect of AMP and histamine, theophylline produced significantly greater protection against AMP whether airway calibre was assessed as Vmax30 or FEV1. The differential effects of theophylline and enprofylline against AMP, but not histamine or baseline airway calibre suggest that adenosine antagonism has little role to play in the acute bronchodilator actions of xanthines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562472     DOI: 10.1016/0952-0600(89)90039-2

Source DB:  PubMed          Journal:  Pulm Pharmacol        ISSN: 0952-0600


  10 in total

Review 1.  Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action.

Authors:  W H Ng; R Polosa; M K Church
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

2.  Mechanism of adenosine-induced airways obstruction in allergic guinea pigs.

Authors:  Sandra Keir; Victoria Boswell-Smith; Domenico Spina; Clive Page
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

Review 3.  Adenosine receptors and asthma.

Authors:  R A Brown; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 4.  Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma?

Authors:  R Polosa; S T Holgate
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

Review 5.  The resurgence of A2B adenosine receptor signaling.

Authors:  Carol M Aherne; Emily M Kewley; Holger K Eltzschig
Journal:  Biochim Biophys Acta       Date:  2010-05-28

Review 6.  Antihistamines in the treatment of asthma.

Authors:  S T Holgate
Journal:  Clin Rev Allergy       Date:  1994

7.  Disparity in FcεRI-induced degranulation of primary human lung and skin mast cells exposed to adenosine.

Authors:  Gregorio Gomez; Wei Zhao; Lawrence B Schwartz
Journal:  J Clin Immunol       Date:  2011-03-25       Impact factor: 8.317

8.  The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma.

Authors:  Stephen T Holgate
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 9.  Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease.

Authors:  Riccardo Polosa; Michael R Blackburn
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

10.  Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma.

Authors:  I Feoktistov; I Biaggioni
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.